A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects with Advanced Solid Tumors
Advanced Solid Tumors
18 Years - 99 Years
Endpoint Classification: Safety
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Feb 2021 by MedImmune, LLC
No locations available
Participants will receive MEDI9090 (fixed dose durvalumab Dose 1 and tremelimumab Dose 1) every 4 weeks (Q4W) via a single IV infusion for 4 months (up to 4 doses), followed by monotherapy with durvalumab Q4W via IV infusion until disease progression, treatment discontinuation due to unrelated or treatment-related toxicities, clinical deterioration with durvalumab monotherapy, or treatment discontinuation due to other reasons, whichever occurs first.
MEDI9090 will be administered Q4W via a single IV infusion for 4 months (up to 4 doses).
Durvalumab as a single agent will be administered by IV infusion after participants have completed the prescribed doses of MEDI9090.